The Sigma-2 Receptor and Progesterone Receptor Membrane Component 1 are Different Binding Sites Derived From Independent Genes

EBioMedicine

Volumn 2, Issue 11, 2015, Pages 1806-1813

  Chu, Uyen B ^a   Mavlyutov, Timur A ^a   Chu, Ming Liang ^a   Yang, Huan ^a   Schulman, Amanda ^a   Mesangeau, Christophe ^b   McCurdy, Christopher R ^b   Guo, Lian Wang ^a   Ruoho, Arnold E ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b UNIVERSITY OF MISSISSIPPI   (United States)

Author keywords

Clustered regularly interspaced short palindromic repeats (CRISPR) Cas9 knockout; Progesterone receptor membrane component 1 (PGRMC1); Sigma 2 receptor (S2R); 125I Iodoazido fenpropimorph ( 125I IAF); 3H 1,3 Di o tolylguanidine ( 3H DTG)

Indexed keywords

1,3 DI 2 TOLYLGUANIDINE; GUANIDINE DERIVATIVE; HALOPERIDOL; IODINE 125; LIPOFECTAMINE; PENTAZOCINE; PROGESTERONE BINDING PROTEIN; PROGESTERONE RECEPTOR; SIGMA 2 OPIATE RECEPTOR; UNCLASSIFIED DRUG; MEMBRANE PROTEIN; PGRMC1 PROTEIN, HUMAN; PROGESTERONE; PROTEIN BINDING; SIGMA OPIATE RECEPTOR; SIGMA-2 RECEPTOR;

ANIMAL CELL; ARTICLE; CLUSTERED REGULARLY INTERSPACED SHORT PALINDROMIC REPEAT; CONTROLLED STUDY; GENE INACTIVATION; GENE OVEREXPRESSION; GENETIC TRANSFECTION; KNOCKOUT GENE; MAXIMUM BINDING CAPACITY; NONHUMAN; PHOSPHORYLATION; PHOTOACTIVATION; PHOTOAFFINITY LABELING; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; RAT; WESTERN BLOTTING; ALTERNATIVE RNA SPLICING; ANIMAL; BINDING SITE; CELL LINE; CHEMISTRY; GENE EXPRESSION; GENE ORDER; GENE VECTOR; GENETICS; HUMAN; METABOLISM; MOLECULAR GENETICS; MOUSE; NUCLEOTIDE SEQUENCE;

ALTERNATIVE SPLICING; ANIMALS; BASE SEQUENCE; BINDING SITES; CELL LINE; GENE EXPRESSION; GENE KNOCKOUT TECHNIQUES; GENE ORDER; GENETIC VECTORS; HUMANS; MEMBRANE PROTEINS; MICE; MOLECULAR SEQUENCE DATA; PROGESTERONE; PROTEIN BINDING; RATS; RECEPTORS, PROGESTERONE; RECEPTORS, SIGMA;

EID: 84958834594     PISSN: None     EISSN: 23523964     Source Type: Journal    
DOI: 10.1016/j.ebiom.2015.10.017     Document Type: Article

References (38)

1. Abate C., Niso M., Infantino V., Menga A., Berardi F. Elements in support of the 'non-identity' of the PGRMC1 protein with the sigma2 receptor. Eur. J. Pharmacol. 2015, 758:16-23.
2. Bali N., Arimoto J.M., Morgan T.E., Finch C.E. Progesterone antagonism of neurite outgrowth depends on microglial activation via Pgrmc1/S2R. Endocrinology 2013, 154:2468-2480.
3. Bowen W.D., Hellewell S.B., Mcgarry K.A. Evidence for a multi-site model of the rat brain sigma receptor. Eur. J. Pharmacol. 1989, 163:309-318.
4. Cassano G., Gasparre G., Contino M., Niso M., Berardi F., Perrone R., Colabufo N.A. The sigma-2 receptor agonist PB28 inhibits calcium release from the endoplasmic reticulum of SK-N-SH neuroblastoma cells. Cell Calcium 2006, 40:23-28.
5. Chu U.B., M.T A., Chu M.-L., Yang H., Mesangeau C., McCurdy C.R., Guo L.-W., Ruoho A.E. The 18 kDa sigma-2 receptor and PGRMC1 are derived from separate genes. Experimental Biology Meeting 2015, (LB511).
6. Colabufo N.A., Berardi F., Abate C., Contino M., Niso M., Perrone R. Is the sigma2 receptor a histone binding protein?. J. Med. Chem. 2006, 49:4153-4158.
7. Cong L., Ran F.A., Cox D., Lin S., Barretto R., Habib N., Hsu P.D., Wu X., Jiang W., Marraffini L.A., Zhang F. Multiplex genome engineering using CRISPR/Cas systems. Science 2013, 339:819-823.
8. Crawford K.W., Bowen W.D. Sigma-2 receptor agonists activate a novel apoptotic pathway and potentiate antineoplastic drugs in breast tumor cell lines. Cancer Res. 2002, 62:313-322.
9. Doudna J.A., Charpentier E. Genome editing. The new frontier of genome engineering with CRISPR-Cas9. Science 2014, 346:1258096.
10. Fontanilla D., Hajipour A.R., Pal A., Chu U.B., Arbabian M., Ruoho A.E. Probing the steroid binding domain-like I (SBDLI) of the sigma-1 receptor binding site using N-substituted photoaffinity labels. Biochemistry 2008, 47:7205-7217.
11. Fontanilla D., Johannessen M., Hajipour A.R., Cozzi N.V., Jackson M.B., Ruoho A.E. The hallucinogen N,N-dimethyltryptamine (DMT) is an endogenous sigma-1 receptor regulator. Science 2009, 323:934-937.
12. Gebreselassie D., Bowen W.D. Sigma-2 receptors are specifically localized to lipid rafts in rat liver membranes. Eur. J. Pharmacol. 2004, 493:19-28.
13. Guo L.W., Hajipour A.R., Karaoglu K., Mavlyutov T.A., Ruoho A.E. Development of benzophenone-alkyne bifunctional sigma receptor ligands. Chembiochem 2012, 13:2277-2289.
14. Hanner M., Moebius F.F., Flandorfer A., Knaus H.G., Striessnig J., Kempner E., Glossmann H. Purification, molecular cloning, and expression of the mammalian sigma1-binding site. Proc. Natl. Acad. Sci. U. S. A. 1996, 93:8072-8077.
15. Hellewell S.B., Bowen W.D. A sigma-like binding site in rat pheochromocytoma (PC12) cells: decreased affinity for (+)-benzomorphans and lower molecular weight suggest a different sigma receptor form from that of guinea pig brain. Brain Res. 1990, 527:244-253.
16. Hellewell S.B., Bruce A., Feinstein G., Orringer J., Williams W., Bowen W.D. Rat liver and kidney contain high densities of sigma 1 and sigma 2 receptors: characterization by ligand binding and photoaffinity labeling. Eur. J. Pharmacol. 1994, 268:9-18.
17. Hornick J.R., Xu J., Vangveravong S., Tu Z., Mitchem J.B., Spitzer D., Goedegebuure P., Mach R.H., Hawkins W.G. The novel sigma-2 receptor ligand SW43 stabilizes pancreas cancer progression in combination with gemcitabine. Mol. Cancer 2010, 9:298.
18. 3H]SKF 10047 binding sites in rat brain membranes: evidence of multiplicity. Eur. J. Pharmacol. 1987, 136:231-234.
19. Itzhak Y., Kassim C.O. Clorgyline displays high affinity for sigma binding sites in C57BL/6 mouse brain. Eur. J. Pharmacol. 1990, 176:107-108.
20. Izzo N.J., Xu J., Zeng C., Kirk M.J., Mozzoni K., Silky C., Rehak C., Yurko R., Look G., Rishton G., Safferstein H., Cruchaga C., Goate A., Cahill M.A., Arancio O., Mach R.H., Craven R., Head E., Levine H., Spires-Jones T.L., Catalano S.M. Alzheimer's therapeutics targeting amyloid beta 1-42 oligomers II: sigma-2/PGRMC1 receptors mediate Abeta 42 oligomer binding and synaptotoxicity. PLoS One 2014, 9.
21. Kashiwagi H., Mcdunn J.E., Simon P.O., Goedegebuure P.S., Vangveravong S., Chang K., Hotchkiss R.S., Mach R.H., Hawkins W.G. Sigma-2 receptor ligands potentiate conventional chemotherapies and improve survival in models of pancreatic adenocarcinoma. J. Transl. Med. 2009, 7:24.
22. Martin W.R., Eades C.G., Thompson J.A., Huppler R.E., Gilbert P.E. The effects of morphine- and nalorphine-like drugs in the nondependent and morphine-dependent chronic spinal dog. J. Pharmacol. Exp. Ther. 1976, 197:517-532.
23. Matsumoto R.R., Nguyen L., Kaushal N., Robson M.J. Sigma (sigma) receptors as potential therapeutic targets to mitigate psychostimulant effects. Adv. Pharmacol. 2014, 69:323-386.
24. Mir S.U., Schwarze S.R., Jin L., Zhang J., Friend W., Miriyala S., St Clair D., Craven R.J. Progesterone receptor membrane component 1/Sigma-2 receptor associates with MAP1LC3B and promotes autophagy. Autophagy 2013, 9:1566-1578.
25. Morris D.I., Speicher L.A., Ruoho A.E., Tew K.D., Seamon K.B. Interaction of forskolin with the P-glycoprotein multidrug transporter. Biochemistry 1991, 30:8371-8379.
26. Nicholson H., Comeau A., Mesangeau C., McCurdy C.R., Bowen W.D. Characterization of CM572, a selective irreversible partial agonist of the Sigma-2 receptor with antitumor activity. J. Pharmacol. Exp. Ther. 2015.
27. Pal A., Hajipour A.R., Fontanilla D., Ramachandran S., Chu U.B., Mavlyutov T., Ruoho A.E. Identification of regions of the sigma-1 receptor ligand binding site using a novel photoprobe. Mol. Pharmacol. 2007, 72:921-933.
28. Peluso J.J., Romak J., LIU X. Progesterone receptor membrane component-1 (PGRMC1) is the mediator of progesterone's antiapoptotic action in spontaneously immortalized granulosa cells as revealed by PGRMC1 small interfering ribonucleic acid treatment and functional analysis of PGRMC1 mutations. Endocrinology 2008, 149:534-543.
29. Quirion R., Bowen W.D., Itzhak Y., Junien J.L., Musacchio J.M., Rothman R.B., Su T.P., Tam S.W., Taylor D.P. A proposal for the classification of sigma binding sites. Trends Pharmacol. Sci. 1992, 13:85-86.
30. Ruoho A.E., G.L.W., Hajipour A.R., Karaoglu K., Mavlyutov T.A., Chu U.B., Yang J. Will the true sigma-2 receptor please stand up?. Neuroscience Meeting 2013, (631.08/U1).
31. Sanjana N.E., Shalem O., Zhang F. Improved vectors and genome-wide libraries for CRISPR screening. Nat. Methods 2014, 11:783-784.
32. Vilner B.J., Bowen W.D. Sigma receptor-active neuroleptics are cytotoxic to C6 glioma Cells in culture. Eur. J. Pharmacol. 1993, 244:199-201.
33. Vilner B.J., Bowen W.D. Modulation of cellular calcium by sigma-2 receptors: release from intracellular stores in human SK-N-SH neuroblastoma cells. J. Pharmacol. Exp. Ther. 2000, 292:900-911.
34. Vilner B.J., John C.S., Bowen W.D. Sigma-1 and sigma-2 receptors are expressed in a wide variety of human and rodent tumor cell lines. Cancer Res. 1995, 55:408-413.
35. Weber E., Sonders M., Quarum M., Mclean S., Pou S., Keana J.F. 1,3-Di(2-[5-3H]tolyl)guanidine: a selective ligand that labels sigma-type receptors for psychotomimetic opiates and antipsychotic drugs. Proc. Natl. Acad. Sci. U. S. A. 1986, 83:8784-8788.
36. Wheeler K.T., Wang L.M., Wallen C.A., Childers S.R., Cline J.M., Keng P.C., Mach R.H. Sigma-2 receptors as a biomarker of proliferation in solid tumours. Br. J. Cancer 2000, 82:1223-1232.
37. Xu J., Zeng C., Chu W., Pan F., Rothfuss J.M., Zhang F., Tu Z., Zhou D., Zeng D., Vangveravong S., Johnston F., Spitzer D., Chang K.C., Hotchkiss R.S., Hawkins W.G., Wheeler K.T., Mach R.H. Identification of the PGRMC1 protein complex as the putative sigma-2 receptor binding site. Nat. Commun. 2011, 2:380.
38. Zufferey R., Dull T., Mandel R.J., Bukovsky A., Quiroz D., Naldini L., Trono D. Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery. J. Virol. 1998, 72:9873-9880.